Sevelamer

Nephrology Dialysis Transplantation

Volumn 23, Issue 6, 2008, Pages 2101-

  Wrong, Oliver ^a   Harland, Clive ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLESTIPOL; SEVELAMER;

CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); DIALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; HYPERPHOSPHATEMIA; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

EID: 44449111897     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn165     Document Type: Letter

References (6)

1. Palmer SC, Craig JC, Strippoli GFM. Sevelamer: a promising but unproven drug. Nephrol Dial Transplant 2007; 22: 2742-2745
2. Tonelli M, Wiebe N, Culleton B et al. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22: 2856-2866
3. Manns B, Klarenbach S, Lee H et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007; 22: 2867-2878
4. Silver, J The details bedevil DCOR. Kidney Internat 2007; 72: 1041-1043
5. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Internat 2007; 72: 1130-1137
6. Wrong O, Harland C. Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiol 2007; 107: 17-33